hotspot -WSS

hotspot

author：comprehensive 2025-09-27 19:38:14 - browse：7

Illustration of a red heart. -- health coverage from STAT — Adobe

Novo Nordisk’s obesity drug Wegovy cut the risk of major heart complications by 20% in a closely watched trial, results that could streamline insurance coverage and spur even greater demand for the highly popular therapy.

The milestone Select trial of about 17,500 patients is the first to show that an obesity medication leads to long-term cardiovascular benefits. The company reported only the topline figure in a press release Tuesday, and did not break out the reductions it said were seen in heart attacks, strokes, and cardiovascular deaths — the combined components of the study’s primary outcome. It said all three contributed to the decrease in cardiovascular events in the group that received Wegovy compared with participants given a placebo.

The 20% reduction was greater than many observers were expecting. In a research note Tuesday, Jefferies analysts called the results a “best case” outcome. “If they play baseball in Denmark,” Barclays analyst Emily Field wrote in a note, “Wegovy just hit a home run.”

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： The most pressing bird flu mysteries scientists want answered

knowledge

leisure time

WSS

FDA approves Moderna’s RSV vaccine, its second licensed product

Regeneron agrees to White House price limits on anti

Sutter Health’s antitrust win overturned by appeals court

How CO2 helps viruses stay alive longer in the air

CMS got Medicare Advantage quality rating wrong, judge rules

Private equity could exacerbate cardiology's overuse problem, experts fear

hotspot

hotspot

Wikipedia

The cancer drug shortage isn’t new — and neither are the solutions

FDA approves Moderna’s RSV vaccine, its second licensed product

Medical leaders decry Supreme Court decision on affirmative action

Congress needs to close a vaccine

Drug repurposing or repositioning? The language matters

Congress needs to close a vaccine

Cancer drug shortages should be causing more outrage

The most pressing bird flu mysteries scientists want answered

Peter Hotez and the public health issue of online harassment

PEPFAR is under serious threat — and so is global health

leisure time

Take antibiotics after sex, CDC recommends for certain risk groups

CMS got Medicare Advantage quality rating wrong, judge rules

FDA proposes changes to key medical devices approval pathway

What to make of Biden’s latest efforts on cancer research

FDA proposes changes to key medical devices approval pathway

Regeneron agrees to White House price limits on anti

knowledge

leisure time

leisure time

hotspot